COW: Carbohydrate Oxidation in Elite Wheelchair Racers During Marathon Simulation

Sponsor
University of Illinois at Urbana-Champaign (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04145050
Collaborator
(none)
12
1
3
19
0.6

Study Details

Study Description

Brief Summary

To examine the effect of varying amounts of carbohydrate ingestion on performance, gastrointestinal experiences, and other physiological markers in elite wheelchair racers during a simulated marathon.

Condition or Disease Intervention/Treatment Phase
  • Other: Carbohydrate dosing
N/A

Detailed Description

The metabolic demands created by endurance activities, which include muscle and liver glycogen depletion as well as losses in body fluids and electrolytes, are significant limitations to the performance potential of the athlete. For this reason, a well-supported recommendation exists for such athletes to consume a carbohydrate (CHO) formula, in particular, one containing electrolytes during their activity. Furthermore, the current CHO recommendations to support prolonged activity have been developed specifically for able-bodied athletes, thus are potentially inappropriate for para athletes.

Metabolic and physiological functions are altered in individuals with physical disabilities, so it is unknown how transferable these recommendations are to para athletes. As such, it is important to understand this population's unique carbohydrate requirements for performance optimization.

Recently, our group showed stable elevated circulating glucose concentrations by utilizing two different sources of CHO dosed at 60 g/h when compared to water. Significantly improved performance was observed with both CHO conditions. These findings, combined with studies showing decreased net muscle glycogen degradation during intravenous glucose infusion (3.5 g/min), show the importance of plasma glucose concentration for sustained performance. Therefore, the purpose of this study is to investigate the SCI-specific responses to exogenous CHO during a full marathon simulation (MS).

Twelve highly trained men and women (20-50 yrs old) will be recruited to the study. The inclusion criteria are: 1.) Best marathon time lower than 2h 2.) and ≥6 months of prior training history. After initial screenings, participants will perform three marathon (MS) trials. In cross-over trials, each subject will participate in a MS trial consisting of a challenge (90% of subject's best marathon time) followed by a time trial (TT) representing the last 10% of the marathon time. During each MS trial, participants will be randomly assigned to receive either water, 30g, or 60g of carbohydrate (CHO) every 15 minutes in the form of a sports nutrition beverage. Repeated blood and breath sampling will occur throughout the MS. These samples will be used to determine glucose concentration, lactate concentration, as well as CHO and fat oxidation. Heart rate, core temperature, blood pressure, ratings of perceived exertion and GI symptoms will also be assessed throughout the MS and after the time trial.

Completion of this research study will help to identify more appropriate CHO recommendations for para athletes to support prolonged endurance exercise. This will aid in the understanding of the unique physiological and metabolic needs of para athletes as compared to their able-bodied counterparts, thus enhancing inclusivity within sports nutrition literature.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
12 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Randomized, Cross-OverRandomized, Cross-Over
Masking:
Double (Participant, Investigator)
Masking Description:
Participants as well as researchers will not be informed of trial intervention
Primary Purpose:
Basic Science
Official Title:
Carbohydrate Oxidation in Elite Wheelchair Racers During Marathon Simulation
Anticipated Study Start Date :
Dec 1, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Carbohydrate Dose: 0 grams carbohydrate

Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.

Other: Carbohydrate dosing
The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.

Experimental: Carbohydrate Dose: 30 grams carbohydrate

Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.

Other: Carbohydrate dosing
The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.

Experimental: Carbohydrate Dose: 60 grams carbohydrate

Participants will be randomly selected, in a cross-over fashion, to ingest 0 grams/hour, 30 grams/ hour, or 60 grams/ hour of carbohydrate beverage throughout each experimental trial.

Other: Carbohydrate dosing
The purpose of this study is to examine effects of different carbohydrate doses during marathon simulation in elite wheelchair racers.

Outcome Measures

Primary Outcome Measures

  1. Performance [10-15 minutes]

    Performance will be measured by time required to complete a 2.6 mile time-trial immediately following marathon simulation

Secondary Outcome Measures

  1. Ratings of gastrointestinal (GI) experiences [Throughout experimental protocol for 1.5 - 2 hours]

    Using a visual analog scale (Visual Analog Symptom Scale), participants will record GI symptoms (from 0-100 whereby higher numbers indicate worse experiences) at various time points throughout experimental trial

  2. Blood Glucose Concentration [Throughout experimental protocol for 1.5 - 2 hours]

    Blood glucose concentration will be measured at various time points throughout experimental trial

  3. Blood Lactate Concentration [Throughout experimental protocol for 1.5 - 2 hours]

    Blood lactate concentration will be measured at various time points throughout experimental trials

  4. Core Temperature [Throughout experimental protocol for 1.5 - 2 hours]

    Core temperature will be measured at various time points throughout experimental trials via ingestible thermometer sensors

  5. Rated Perceived Exertion (RPE) [Throughout experimental protocol for 1.5 - 2 hours]

    RPE, or how hard an athlete feels they are working, will be recorded at various time points throughout the experimental trial

Eligibility Criteria

Criteria

Ages Eligible for Study:
20 Years to 50 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • < 2-hour best marathon time

  • 6 months prior training history

Exclusion Criteria:
    • Chronic Smoking or tobacco use
  • Active cardiovascular disease

  • Diabetes Mellitus or other metabolic disorders

  • Liver kidney, or urinary disease

  • Musculoskeletal/Orthopedic disorders (e.g., osteoarthritis, rheumatoid arthritis, tendinitis, gout, fibromyalgia, patellar tendinopathy, or chronic low back pain)

  • Neuromuscular disorders

  • hypertension

  • Diagnosed GI tract diseases

  • Heart Disease

  • Neurological disease

  • Epilepsy

  • Respiratory disease

  • Pregnancy

  • Contraindications for exercise

  • <6 months of prior training history

Contacts and Locations

Locations

Site City State Country Postal Code
1 Disability Rehababilitation and Education Services Champaign Illinois United States 61820

Sponsors and Collaborators

  • University of Illinois at Urbana-Champaign

Investigators

  • Principal Investigator: Nicholas A Burd, PhD, University of Illinois at Urbana-Champaign

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Nicholas Burd, Primary Investigator, University of Illinois at Urbana-Champaign
ClinicalTrials.gov Identifier:
NCT04145050
Other Study ID Numbers:
  • 20020
First Posted:
Oct 30, 2019
Last Update Posted:
Apr 28, 2021
Last Verified:
Apr 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No

Study Results

No Results Posted as of Apr 28, 2021